Xilio Therapeutics
XLO · Nasdaq · United States
Share price · XLO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when XLO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 3 Nov 2026+8.6%
- 27 Oct 2026+9.6%
- 14 May 2026+13.5%
Nothing announced by XLO that day or the session before.
- 5 May 2026-7.4%
Nothing announced by XLO that day or the session before.
- 24 Mar 2026+6.5%
- 20 Mar 2026+7.8%
Nothing announced by XLO that day or the session before.
- 12 Feb 2026+11.4%
- 21 Jan 2026-4.6%
Nothing announced by XLO that day or the session before.
- 9 Jan 2026-6.0%
- 20 Nov 2025-7.1%
Nothing announced by XLO that day or the session before.
Share of unusual movement by asset
For each asset, the share of XLO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
XTX501events and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 60% |
| Sessions with no dated event | — | 39% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | PD-1/PD-L1 axis; IL-2 receptor βγ (IL-2Rβγ)Multispecific antibody | Non-Small Cell Lung Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $10.0M | $15M | $124M | $6.0M-$14M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $19M | $15M | $138M | $6.4M-$19M operating cash flow | report ↗ |
| 2026-Q1 | $13M | $20M | $152M | $9.5M-$22M operating cash flow | report ↗ |
| 2025-Q3 | $19M | $14M | $106M | $16M-$17M operating cash flow | report ↗ |
| 2025-Q2 | $8.1M | $15M | $123M | $16M-$14M operating cash flow | report ↗ |
| 2025-Q1 | $2.9M | $8.3M | $91M | $13M$29M operating cash flow | report ↗ |
| 2024-Q3 | $2.3M | $11M | $63M | $14M-$14M operating cash flow | report ↗ |
| 2024-Q2 | $2.4M | $11M | $77M | $14M$20M operating cash flow | report ↗ |
| 2024-Q1 | — | $10M | $37M | $17M-$11M operating cash flow | report ↗ |
| 2023-Q3 | — | $11M | $61M | $17M-$13M operating cash flow | report ↗ |
| 2023-Q2 | — | $13M | $77M | $19M-$17M operating cash flow | report ↗ |
| 2023-Q1 | — | $16M | $95M | $23M-$25M operating cash flow | report ↗ |
| 2022-Q3 | — | $13M | $141M | $20M-$20M operating cash flow | report ↗ |
| 2022-Q2 | — | $16M | $161M | $25M-$17M operating cash flow | report ↗ |
| 2022-Q1 | — | $15M | $179M | $21M-$21M operating cash flow | report ↗ |
| 2021-Q3 | — | $10M | $101M | $16M-$21M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $44M | $56M | $139M | $8.8M-$5.0M operating cash flow | report ↗ |
Xilio reported full-year 2025 revenue of $43.77M, up 590.4% YoY, with R&D spend of $56.04M, up 36.0% YoY. Cash and equivalents totaled $139.34M, and the company recorded a net loss of $35.04M, with a quarterly net burn of $35.04M.
Management guided that existing cash should fund operations through the end of 2027, excluding potential milestone payments and up to $36.2M in Series C warrant proceeds. XTX501 remains on track for an IND submission in mid-2026 and Phase 1 initiation in the second half of 2026, while masked T cell engager programs targeting CLDN18.2 and PSMA/STEAP1 are advancing, with new CLDN18.2 preclinical data planned for AACR. The efarindodekin alfa Phase 2 trial continues, with an option data package to Gilead expected in the first half of 2027, and the company noted recent warrant exercises, an AbbVie milestone, and a February 2026 follow-on offering.
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($44K), 2 sales ($6K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-01 | Houvras Yariv · CHIEF MEDICAL OFFICER | Award / grant (derivative) | 105,000 | — | — | Form 4 |
| 2026-06-11 | Brennan Aoife · director | Award / grant (derivative) | 5,000 | — | — | Form 4 |
| 2026-06-11 | Bonstein Sara · director | Award / grant (derivative) | 5,000 | — | — | Form 4 |
| 2026-06-11 | ROSS ROBERT W. · director | Award / grant (derivative) | 5,000 | — | — | Form 4 |
| 2026-06-11 | Xu Yuan · director | Award / grant (derivative) | 5,000 | — | — | Form 4 |
| 2026-06-11 | Curran Daniel J. · director | Award / grant (derivative) | 5,000 | — | — | Form 4 |
| 2026-06-11 | Shannon James Samuel · director | Award / grant (derivative) | 5,000 | — | — | Form 4 |
| 2026-06-11 | Bello Akintunde Olatokumbo · director | Award / grant (derivative) | 5,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 23 reporting institutions held 2.0M shares ($16.4M, 27.9% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Bain Capital Life Sciences Investors, LLC | 664,021 | $5.6M |
| 2 | Frazier Life Sciences Management, L.P. | 422,505 | $3.6M |
| 3 | Sio Capital Management, LLC | 152,464 | $1.3M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 123,660 | $1.0M |
| 5 | Caligan Partners LP | 112,128 | $943K |
| 6 | Merck & Co., Inc. | 105,982 | $891K |
| 7 | Stonepine Capital Management, LLC | 64,162 | $540K |
| 8 | MORGAN STANLEY | 57,493 | $484K |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 49,566 | $417K |
| 10 | AJU IB Investment Co., Ltd. | 47,695 | $401K |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 37,197 | $313K |
| 12 | FMR LLC | 36,558 | $307K |
| 13 | VANGUARD FIDUCIARY TRUST CO | 28,475 | $239K |
| 14 | Velan Capital Investment Management LP | 14,285 | $120K |
| 15 | Ghisallo Capital Management LLC | 13,800 | $116K |